Key Pfizer-Sponsored Data Presentations at the European Society for - PDF document

Key Pfizer-Sponsored Data Presentations at the European Society for Medical Oncology (ESMO) Annual Meeting 2018 The embargo on data featured in a poster display session will lift on Tuesday, October 9, at 00:05 CEST. The embargo on data presented as a proffered paper (oral) or poster discussion will lift on Friday, October 19, at 12:00 CEST. Avelumab: (LBA6_PR) JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Robert J. Motzer. Sunday, October 21. Session Type: Proffered Paper. Presentation Time: 17:20 - 17:35 CEST. Location: Hall A2 – Room 18. (Abstract 1282P) Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients with metastatic merkel cell carcinoma (mMCC) treated with avelumab. Sandra P. D'Angelo. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 1290P) Avelumab in European patients with metastatic merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program. Paul Nathan. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 1291P) Cost-effectiveness of avelumab vs standard care for the treatment of patients with metastatic merkel cell carcinoma (mMCC). Murtuza Bharmal. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 659P) Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated results from the phase 1b JAVELIN Solid Tumor JPN trial. Toshihiko Doi. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 877P) First-line or second-line avelumab monotherapy in patients with advanced renal cell carcinoma (aRCC) enrolled in the phase 1b JAVELIN Solid Tumor trial. Ulka N. Vaishampayan. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 1241TiP) JAVELIN PARP Medley: a phase 1b/2 study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Timothy A. Yap. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Axitinib: (Abstract 863O) Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. Marine Gross-Goupil . Saturday, October 20. Session Type: Proffered Paper. Presentation Time: 9:15 – 10:45 CEST. Location: Hall A1 – Room 17. Bosutinib: (Abstract 1033P) Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: subgroup analysis from the BELA trial. Hemant Malhotra. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. 1

Crizotinib: (Abstract 1396P) Efficacy and safety of crizotinib in previously treated patients with ALK+ advanced non-small- cell lung c ancer (NSCLC) aged ≥65 years. Denis Moro-Sibilot. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. (Abstract 1397P) Long-term safety of crizotinib in previously treated patients with ALK-positive advanced/metastatic non-small-cell lung cancer (NSCLC). Lucio Crinò. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Enzalutamide: (Abstract 807P) Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: results from the PROSPER study. Bertrand Tombal. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 805P) A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer (CRPC): results of PROSPER by age and region. Karim Fizazi. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. Lorlatinib: (Abstract 1380PD) Efficacy of lorlatinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. Benjamin J. Solomon. Friday, October 19. Session Type: Poster Discussion. Presentation Time: 14:00 – 15:00 CEST. Location: ICM – Room 14B. (Abstract 1399P) Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). Solange Peters. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Palbociclib: (LBA2) Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Massimo Cristofanilli. Saturday, October 20. Session Type: Proffered Paper. Presentation Time: 17:00 - 17:15 CEST. Location: Hall 2A – Room 18. (Abstract 338P) Real world treatment patterns associated with palbociclib combination therapy in Germany: results from the IRIS Study. Debanjali Mitra. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 332P) Clinical outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2. Hope S. Rugo. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. 2

(Abstract 356P) A prospective observational study of mobile application-based patient-reported outcomes in advanced breast cancer: interim baseline data from the MADELINE study. Dawn Odom. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 344P) First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor - positive (HR+) advanced breast cancer – a prospective, multicenter, noninterventional study. Joanne L. Blum. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 334P) Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. Michelino De Laurentiis. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. Sunitinib: (Abstract 881P) Correlations between disease-free survival (DFS) and overall survival (OS) in patients with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial. Daniel J. George. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 916P) Sunitinib tolerance following an initial exposure period: results of longitudinal PRO data from S- TRAC study. Daniel J. George. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. Talazoparib: (Abstract 292O) Patient-reported outcomes (PRO) in patients with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Hope S. Rugo. Monday, October 20. Session Type: Proffered Paper. Presentation Time: 11:00 – 12:45 CEST. Location: Hall A2 – Room 18. (Abstract 1567PD) Genetic testing of BRCA mutations in breast cancer across Europe: barriers and opportunities. Maia Thrift-Perry. Saturday, October 20. Session Type: Poster Discussion. Presentation Time: 9:15 – 10:30 CEST. Location: Hall B4 – Room 19. (Abstract 303P) EMBRACA: Comparison of efficacy and safety of talazoparib and physician's choice of therapy (PCT) in patients with advanced breast cancer (ABC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Miguel Martín. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 304P) EMBRACA: Efficacy and safety in comparing talazoparib with physician's choice of therapy (PCT) in patients with advanced breast cancer (ABC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Anthony Gonçalves. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 305P) Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase 3 EMBRACA trial. Yanke Yu. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. 3